Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).

Inclusion Criteria: * Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics: * Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures; * \> 18/= and \< 37 years old; * BMI between 18 and 28 kg/m2; * Less than 3 previous completed IVF cycles; * Basal FSH level less than 10 IU/L once within 6 months prior to the study; * Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS; * Normal or clinically insignificant haematology and blood chemistry values. Exclusion Criteria: * Primary ovarian failure or women known as poor responders; * Signs of PCO, according to the Rotterdam Criteria; * At least one ovary inaccessible for oocyte retrieval; * One or more ovarian cysts \> 10 mm; * Hydrosalpinx that have not been surgically removed or ligated; * Stage III or IV endometriosis; * Patients affected by pathologies associated with any contraindication of being pregnant; * Hypersensitivity to the study medication; * Abnormal bleeding of undetermined origin; * Uncontrolled thyroid or adrenal dysfunction; * Neoplasias; * PAP smear III within the last 2 years; * Severe impairment of the renal and/or hepatic functions; * Lactation; * Hyperprolactinaemia; * Participation in a concurrent clinical trial or in another trial within the past four weeks; * Use of concomitant medication that might interfere with study evaluations.